首页> 外文期刊>Expert opinion on investigational drugs >Recent advances in the treatment of non-alcoholic fatty liver disease
【24h】

Recent advances in the treatment of non-alcoholic fatty liver disease

机译:非酒精性脂肪肝治疗的最新进展

获取原文
获取原文并翻译 | 示例
       

摘要

Non-alcoholic steatohepatitis is a liver disease strongly associated with features of the metabolic syndrome.It is part of the disease spectrum of nonalcoholic fatty liver disease,which is now thought to be the most common cause of chronic liver disease in the US and other Western countries.Initially this condition was considered innocuous but it is now recognised as having the potential to progress to cirrhosis and its complications.The role of insulin resistance and oxidative stress in its pathogenesis is increasingly accepted.Current investigations are directed towards a better understanding of the natural history,pathogenesis and development of treatment strategies.Several therapeutic modalities,including antioxidants,insulin-sensitising agents and lipid-lowering agents,have been evaluated for the treatment of these patients,mostly in small clinical trials.Despite promising results,no therapy has demonstrated a proven benefit.
机译:非酒精性脂肪性肝炎是一种与代谢综合征特征密切相关的肝脏疾病,它是非酒精性脂肪肝疾病谱的一部分,现在被认为是美国和其他西方国家慢性肝病的最常见原因。最初被认为是无害的,但现在被认为具有发展为肝硬化及其并发症的潜力。胰岛素抵抗和氧化应激在其发病机理中的作用已被越来越多的人接受。目前的研究旨在更好地了解自然病史,发病机理和治疗策略的发展。已评估了包括抗氧化剂,胰岛素增敏剂和降脂剂在内的几种治疗方式,主要是在小型临床试验中进行了评估。尽管有希望的结果,但尚无治疗方法证明有实效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号